SCHEMBL3751277

SCHEMBL3751277

COc1c(Cl)c(C=C(C)C(=O)NCCO)c(OC)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.50
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
IDO1 P14902 1/20 0.37
SLC2A1 P11166 2/20 0.37
MAPT P10636 1/20 0.35
PRNP P04156 1/20 0.34
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34
DRD3 P35462 6/20 0.34
DRD2 P14416 4/20 0.34
DRD4 P21917 2/20 0.34
SIGMAR1 Q99720 1/20 0.33
PDE4D Q08499 1/20 0.33
MDM4 O15151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751273 1.00 APEX1 (0.50) APEX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL20123260 0.92 APEX1 (0.47) APEX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL3751108 0.82 DRD2 (0.42) MAPTDRD2
SCHEMBL3750250 0.79 AKR1C3 (0.45) APEX1ALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL3750251 0.79 AKR1C3 (0.45) APEX1ALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL3754493 0.79 AKR1C3 (0.45) APEX1ALDH1A1SMN1; SMN2KDM4ECYP1A2
SCHEMBL13894545 0.79 APEX1 (0.53) APEX1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL13079652 0.77 MAPT (0.42) ALDH1A1SMN1; SMN2RAB9AKDM4ECYP1A2
SCHEMBL13080065 0.77 MAPT (0.42) ALDH1A1SMN1; SMN2RAB9AKDM4ECYP1A2
SCHEMBL13894723 0.76 SLC2A1 (0.35) APEX1ALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203161-B1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF UNIV INDIANA RES & TECH CORP (US) 2018-05-09 EP disclosed
US-9089605-B2 Quinone derivatives, pharmaceutical compositions, and uses thereof INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-07-28 US disclosed
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 APEX1 1/4885ALDH1A1 210/4885SMN1; SMN2 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.